Safety and Pharmacokinetics of Besylsartan Tablet in Healthy Male Subject
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Besylsartan
Amosartan
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Body Mass Index (BMI) between 18 and 30
- Healthy as determined by a responsible physician
Exclusion Criteria:
- History of clinically significant disease
- Any chronic disease
- Creatine clearance less than 50ml/min
- Hypotension (100mmHg/60mmHg)
- Treatment of barbital type drug within 1 month
- Administration of herbal medicine within 7 days
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Besylsartan
Amosartan
Arm Description
amlodipine besylate 6.944mg+losartan K 100mg
amlodipine besylate 7.841mg+losartan K 100mg
Outcomes
Primary Outcome Measures
Change from baseline in blood concentration of Amlodipine
Detect the change of blood concentration of Amlodipine by LC-MS/MS
Change from baseline in blood concentration of Losartan
Detect the change of blood concentration of Losartan by LC-MS/MS
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02504606
Brief Title
Safety and Pharmacokinetics of Besylsartan Tablet in Healthy Male Subject
Official Title
A Randomized, Open-label, Single Dose, 2-Treatment, 2-Period, 2-Way Crossover Study to Assess Safety and Pharmacokinetics of Besylsartan Tablet in Healthy Male Subject
Study Type
Interventional
2. Study Status
Record Verification Date
July 2015
Overall Recruitment Status
Completed
Study Start Date
September 2014 (undefined)
Primary Completion Date
October 2014 (Actual)
Study Completion Date
October 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Huons Co., Ltd.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This clinical trial was evaluated to compare the safety and pharmacokinetics of Besylsartan with Amosartan, which was available commercially after single oral dose in healthy male subjects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
60 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Besylsartan
Arm Type
Experimental
Arm Description
amlodipine besylate 6.944mg+losartan K 100mg
Arm Title
Amosartan
Arm Type
Active Comparator
Arm Description
amlodipine besylate 7.841mg+losartan K 100mg
Intervention Type
Drug
Intervention Name(s)
Besylsartan
Intervention Description
Amlodipin besylate 6.944mg+Losartan K 100mg
Intervention Type
Drug
Intervention Name(s)
Amosartan
Intervention Description
Amlodipin besylate 7.841mg+Losartan K 100mg
Primary Outcome Measure Information:
Title
Change from baseline in blood concentration of Amlodipine
Description
Detect the change of blood concentration of Amlodipine by LC-MS/MS
Time Frame
144 hour
Title
Change from baseline in blood concentration of Losartan
Description
Detect the change of blood concentration of Losartan by LC-MS/MS
Time Frame
10 hour
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Body Mass Index (BMI) between 18 and 30
Healthy as determined by a responsible physician
Exclusion Criteria:
History of clinically significant disease
Any chronic disease
Creatine clearance less than 50ml/min
Hypotension (100mmHg/60mmHg)
Treatment of barbital type drug within 1 month
Administration of herbal medicine within 7 days
12. IPD Sharing Statement
Learn more about this trial
Safety and Pharmacokinetics of Besylsartan Tablet in Healthy Male Subject
We'll reach out to this number within 24 hrs